GLSI
vs
S&P 500
GLSI
S&P 500
Over the past 12 months, GLSI has significantly outperformed S&P 500, delivering a return of +119% compared to the S&P 500's +12% growth.
Stocks Performance
GLSI vs S&P 500
Performance Gap
GLSI vs S&P 500
Performance By Year
GLSI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Greenwich Lifesciences Inc
Glance View
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is developing, GP2, a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.
